Entyvio

(vedolizumab)
Entyvio 300 MG Injection
NO BOXED WARNING

Dosage & administration

Important Administration Information

Recommended Dosage


Preparation and Administration Instructions for Intravenous Infusion ( 2.4):


drug label

Entyvio prescribing information

prior authorization

Entyvio prior authorization resources

Most recent Entyvio prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Medicare Prescription Drug Medication Request Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Short Acting Opioid Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Western NY - Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Western NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Feb 27, 2024Arizona - Uniform Prior Authorization Form
Verified: Feb 27, 2024Colorado - Uniform Prior Authorization Form
Verified: Feb 27, 2024Hawaii - Uniform Prior Authorization Form
Verified: Feb 27, 2024Illinois - Uniform Prior Authorization Form
Verified: Feb 27, 2024Indiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Louisiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Michigan - Uniform Prior Authorization Form
Verified: Feb 27, 2024Minnesota - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Mexico - Uniform Prior Authorization Form
Verified: Feb 27, 2024Oregon - Uniform Prior Authorization Form
Verified: Feb 27, 2024Texas - Uniform Prior Authorization Form
Complete Letter of Medical Necessity
Coverage Authorization Appeals
Appeal Letter For Rejected Claim
Learn More

Benefits investigation

Entyvio Connect Enrollment Form
Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information
Learn More

financial assistance

Entyvio financial assistance options

Co-pay savings program

commercial only
Entyvio Connect Enrollment Form
Enroll in Patient Savings Program
Co-Pay Claim Form
Learn More

Bridge program

commercial only
Entyvio Connect Enrollment Form
Start Program [Awaiting Approval]
Bridge Program [Temporary loss or gap in coverage]
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Patient Assistance Application Form
Learn More

PubMed™ | Entyvio

Entyvio PubMed™ News

patient education

Entyvio patient education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

Patient Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure- Spanish
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Infusion Guide
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Entyvio Connect Patient Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Entyvio
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Entyvio: Ulcerative Colitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Entyvio: Crohn's Disease
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Continuing Treatment - Traveling
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Entyvio FAQs

Is there a pregnancy exposure registry for ENTYVIO?Yes, there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ENTYVIO during pregnancy. For more information, you can call 1-877-TAKEDA-7 (1-877-825-3327).
What is the risk of using ENTYVIO during pregnancy?Available pharmacovigilance data, data from the ongoing pregnancy registry, and data from published case reports and cohort studies in pregnant women have not identified an ENTYVIO associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. However, there are risks to the mother and the fetus associated with inflammatory bowel disease in pregnancy. It is important to consider these risks in addition to the benefits of using ENTYVIO.
What are the risks associated with inflammatory bowel disease (IBD) in pregnancy?Published data suggest that the risk of adverse pregnancy outcomes in women with IBD is associated with increased disease activity. Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2,500 g) infants, and small for gestational age at birth.
Can ENTYVIO affect immune responses in newborns and infants?ENTYVIO administered during pregnancy could affect immune responses in the in utero-exposed newborn and infant. The clinical significance of low levels of ENTYVIO in utero-exposed infants is unknown. The safety of administering live or live-attenuated vaccines in exposed infants is also unknown.
Is it safe to use ENTYVIO while breastfeeding?Data from a clinical lactation study show the presence of vedolizumab (the active ingredient in ENTYVIO) in human milk. Systemic exposure in a breastfed infant is expected to be low because monoclonal antibodies are largely degraded in the gastrointestinal tract. There are no data on the effects of vedolizumab on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ENTYVIO and any potential adverse effects on the breastfed infant from ENTYVIO or from the underlying maternal condition.
Is ENTYVIO safe for use in pediatric patients?Safety and effectiveness of ENTYVIO in pediatric patients have not been established.
Is ENTYVIO safe for use in geriatric patients?Clinical trials of ENTYVIO did not include sufficient numbers of subjects aged 65 and over.
FAQ Data Source